Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helio S Sader

Showing results (221-230 of 420) with videos related to

Pageof 42
Sort By:
The Journal of Antimicrobial Chemotherapy|February 17, 2009
TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogensRonald N Jones, Gary J Moet, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|July 12, 2015
Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014)Helio S Sader, Mariana Castanheira, David J Farrell, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 13, 2019
Antimicrobial activity of cefoperazone-sulbactam tested against Gram-Negative organisms from Europe, Asia-Pacific, and Latin AmericaHelio S Sader, Cecilia G Carvalhaes, Jennifer M Streit, et al.
Antimicrobial Agents and Chemotherapy|January 11, 2012
Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infectionsHelio S Sader, Douglas J Biedenbach, Susanne Paukner, et al.
Antimicrobial Agents and Chemotherapy|January 1, 2014
Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012Helio S Sader, Mariana Castanheira, Robert K Flamm, et al.
Journal of Clinical Microbiology|August 11, 2017
Determination of Disk Diffusion and MIC Quality Control Guidelines for High-Dose Cefepime-Tazobactam (WCK 4282), a Novel Antibacterial Combination Consisting of a β-Lactamase Inhibitor and a Fourth-Generation CephalosporinStefan Riedel, Michael D Huband, Helio S Sader, et al.
Journal of Global Antimicrobial Resistance|July 24, 2017
Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015)Michael A Pfaller, Rodrigo E Mendes, Helio S Sader, et al.
The Journal of Antimicrobial Chemotherapy|March 8, 2019
Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997-2016)Helio S Sader, Mariana Castanheira, S J Ryan Arends, et al.
The Journal of Antimicrobial Chemotherapy|July 27, 2022
Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19)Helio S Sader, Rodrigo E Mendes, Leonard R Duncan, et al.
Open Forum Infectious Diseases|February 27, 2023
Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019-2021)Helio S Sader, Rodrigo E Mendes, Cecilia G Carvalhaes, et al.
Pageof 42

Showing results (221-230 of 420) with videos related to

Sort By:
Pageof 42
The Journal of Antimicrobial Chemotherapy|February 17, 2009
TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogensRonald N Jones, Gary J Moet, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|July 12, 2015
Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014)Helio S Sader, Mariana Castanheira, David J Farrell, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 13, 2019
Antimicrobial activity of cefoperazone-sulbactam tested against Gram-Negative organisms from Europe, Asia-Pacific, and Latin AmericaHelio S Sader, Cecilia G Carvalhaes, Jennifer M Streit, et al.
Antimicrobial Agents and Chemotherapy|January 11, 2012
Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infectionsHelio S Sader, Douglas J Biedenbach, Susanne Paukner, et al.
Antimicrobial Agents and Chemotherapy|January 1, 2014
Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012Helio S Sader, Mariana Castanheira, Robert K Flamm, et al.
Journal of Clinical Microbiology|August 11, 2017
Determination of Disk Diffusion and MIC Quality Control Guidelines for High-Dose Cefepime-Tazobactam (WCK 4282), a Novel Antibacterial Combination Consisting of a β-Lactamase Inhibitor and a Fourth-Generation CephalosporinStefan Riedel, Michael D Huband, Helio S Sader, et al.
Journal of Global Antimicrobial Resistance|July 24, 2017
Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015)Michael A Pfaller, Rodrigo E Mendes, Helio S Sader, et al.
The Journal of Antimicrobial Chemotherapy|March 8, 2019
Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997-2016)Helio S Sader, Mariana Castanheira, S J Ryan Arends, et al.
The Journal of Antimicrobial Chemotherapy|July 27, 2022
Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19)Helio S Sader, Rodrigo E Mendes, Leonard R Duncan, et al.
Open Forum Infectious Diseases|February 27, 2023
Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019-2021)Helio S Sader, Rodrigo E Mendes, Cecilia G Carvalhaes, et al.
Pageof 42